Journal of Clinical Endocrinology & Metabolism, Vol 81, 2041-2046, Copyright © 1996 by Endocrine Society

ARTICLES

RET proto-oncogene point mutations in sporadic neuroendocrine tumors

P Komminoth, J Roth, S Muletta-Feurer, P Saremaslani, WK Seelentag and PU Heitz
Division of Cell and Molecular Pathology, University of Zurich, Switzerland. paulkom@pathol.unizh.ch

We investigated the possible role of the RET proto-oncogene, which has recently been identified as the susceptibility gene for multiple endocrine neoplasia type 2, in the development of sporadic neuroendocrine tumors from different locations. DNA extracted from paraffin-embedded specimens of 112 neuroendocrine tumors was screened for somatic RET point mutations in exons 10, 11, 13, 15, and 16, where recently oncogenic mutations have been described in a subset of sporadic medullary thyroid carcinomas and pheochromocytomas. Methods employed included nonisotopic PCR-based single strand conformation polymorphism (PCR-SSCP) analysis, heteroduplex gel electrophoresis, and restriction enzyme digestion. The nucleotide sequence of samples with aberrant band patterns was identified by nonisotopic direct sequencing of PCR-amplified DNA. Forty-four percent (7/16) of sporadic medullary thyroid carcinomas and 15% (3/20) of pheochromocytomas contained a somatic, heterozygous point mutation at codon 918 of exon 16 (ATG --> ACG) causing a Met --> Thr substitution. None of the remaining 4 parathyroid adenomas, 8 pituitary adenomas, 17 pancreatic neuroendocrine tumors, 11 pulmonary and 10 gastrointestinal carcinoids, 7 small cell lung carcinomas, 5 neuroblastomas, 10 malignant melanomas, or 4 schwannomas contained mutations in any of the five RET exons tested. Although the numbers of each investigated neuroendocrine tumor type are small, our data indicate that oncogenic RET proto-oncogene mutations are involved in the formation of a subset of sporadically occurring medullary thyroid carcinomas and pheochromocytomas but do not appear to be generally important in the formation of other types of sporadically occurring neuroendocrine tumors.

This article has been cited by other articles:

				J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors Endocr. Rev., August 1, 2006; 27(5): 535 - 560. [Abstract] [Full Text] [PDF]

				M. A. Japon, A. G. Urbano, C. Saez, D. I. Segura, A. L. Cerro, C. Dieguez, and C. V. Alvarez Glial-Derived Neurotropic Factor and RET Gene Expression in Normal Human Anterior Pituitary Cell Types and in Pituitary Tumors J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1879 - 1884. [Abstract] [Full Text] [PDF]

				P. Niccoli-Sire, A. Murat, V. Rohmer, S. Franc, G. Chabrier, L. Baldet, B. Maes, F. Savagner, S. Giraud, S. Bezieau, et al. Familial Medullary Thyroid Carcinoma with Noncysteine RET Mutations: Phenotype-Genotype Relationship in a Large Series of Patients J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3746 - 3753. [Abstract] [Full Text] [PDF]

				B. U. Bender, M. Gutsche, S. Gläsker, B. Müller, G. Kirste, C. Eng, and H. P. H. Neumann Differential Genetic Alterations in von Hippel-Lindau Syndrome-Associated and Sporadic Pheochromocytomas J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4568 - 4574. [Abstract] [Full Text]

				J. R Hansford and L. M Mulligan Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis J. Med. Genet., November 1, 2000; 37(11): 817 - 827. [Abstract] [Full Text]

				B. Xu, T. Sano, S. Yamada, C. C. Li, and M. Hirokawa Expression of Corticotropin-Releasing Hormone Messenger Ribonucleic Acid in Human Pituitary Corticotroph Adenomas Associated with Proliferative Potential J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1220 - 1225. [Abstract] [Full Text]

				M. Volante, M. Papotti, J. Roth, P. Saremaslani, E. J. M. Speel, R. V. Lloyd, J. A. Carney, P. U. Heitz, G. Bussolati, and P. Komminoth Mixed Medullary-Follicular Thyroid Carcinoma : Molecular Evidence for a Dual Origin of Tumor Components Am. J. Pathol., November 1, 1999; 155(5): 1499 - 1509. [Abstract] [Full Text] [PDF]

				P. L. M. Dahia and A. B. Grossman The Molecular Pathogenesis of Corticotroph Tumors Endocr. Rev., April 1, 1999; 20(2): 136 - 155. [Abstract] [Full Text]

				B. Gortz, J. Roth, A. Krahenmann, R. R. de Krijger, S. Muletta-Feurer, K. Rutimann, P. Saremaslani, E. J. M. Speel, P. U. Heitz, and P. Komminoth Mutations and Allelic Deletions of the MEN1 Gene Are Associated with a Subset of Sporadic Endocrine Pancreatic and Neuroendocrine Tumors and Not Restricted to Foregut Neoplasms Am. J. Pathol., February 1, 1999; 154(2): 429 - 436. [Abstract] [Full Text] [PDF]

				C. Eng RET Proto-Oncogene in the Development of Human Cancer J. Clin. Oncol., January 1, 1999; 17(1): 380 - 380. [Abstract] [Full Text] [PDF]

				B. U. Bender, C. Altehofer, A. Januszewicz, R. Gartner, H. Schmidt, M. M. Hoffmann, P. H. Heidemann, and H. P. H. Neumann Functioning Thoracic Paraganglioma: Association with Von Hippel-Lindau Syndrome J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3356 - 3360. [Abstract] [Full Text] [PDF]

				D. J. Marsh, Z. Zheng, A. Arnold, S. D. Andrew, D. Learoyd, A. Frilling, P. Komminoth, H. P.H. Neumann, B. A.J. Ponder, B. J. Rollins, et al. Mutation Analysis of Glial Cell Line-Derived Neurotrophic Factor, a Ligand for an RET/Coreceptor Complex, in Multiple Endocrine Neoplasia Type 2 and Sporadic Neuroendocrine Tumors J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3025 - 3028. [Abstract] [Full Text] [PDF]

				M. Siegelman, A. Mohabeer, T. J. Fahey III, G. Tomlinson, C. Mayambala, S. Jafari, W. W. Noll, S. N. Thibodeau, and D. B. Dawson Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET protooncogene associated with inherited medullary thyroid carcinoma Clin. Chem., March 1, 1997; 43(3): 453 - 457. [Abstract] [Full Text] [PDF]